MX2011009277A - Composicion de leucocito activada. - Google Patents

Composicion de leucocito activada.

Info

Publication number
MX2011009277A
MX2011009277A MX2011009277A MX2011009277A MX2011009277A MX 2011009277 A MX2011009277 A MX 2011009277A MX 2011009277 A MX2011009277 A MX 2011009277A MX 2011009277 A MX2011009277 A MX 2011009277A MX 2011009277 A MX2011009277 A MX 2011009277A
Authority
MX
Mexico
Prior art keywords
activated leukocyte
leukocyte composition
methods
compositions
composition
Prior art date
Application number
MX2011009277A
Other languages
English (en)
Spanish (es)
Inventor
Mitchell Shirvan
Eilat Shinar
Orit Frenkel
Adi Zuloff-Shani
Marina Bubis
Eilat Bain
Irene Ginis
Original Assignee
Macrocure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrocure Ltd filed Critical Macrocure Ltd
Publication of MX2011009277A publication Critical patent/MX2011009277A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/19Platelets; Megacaryocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/18Erythrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057Ingredients of undetermined constitution or reaction products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0642Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
MX2011009277A 2009-03-05 2010-03-05 Composicion de leucocito activada. MX2011009277A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20929809P 2009-03-05 2009-03-05
US21158709P 2009-04-01 2009-04-01
PCT/IB2010/000882 WO2010100570A2 (en) 2009-03-05 2010-03-05 Activated leukocyte composition

Publications (1)

Publication Number Publication Date
MX2011009277A true MX2011009277A (es) 2011-12-16

Family

ID=42710060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009277A MX2011009277A (es) 2009-03-05 2010-03-05 Composicion de leucocito activada.

Country Status (15)

Country Link
EP (2) EP2403509B1 (enExample)
JP (2) JP5713924B2 (enExample)
KR (1) KR101548783B1 (enExample)
CN (1) CN102438635B (enExample)
AU (1) AU2010220132B2 (enExample)
BR (1) BRPI1006759A2 (enExample)
CA (2) CA2754190A1 (enExample)
DK (1) DK2403509T3 (enExample)
ES (1) ES2428102T3 (enExample)
IL (1) IL214953A0 (enExample)
MX (1) MX2011009277A (enExample)
PL (1) PL2403509T3 (enExample)
RU (2) RU2548741C2 (enExample)
WO (1) WO2010100570A2 (enExample)
ZA (1) ZA201107269B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574902B2 (en) 2009-03-05 2013-11-05 Macrocure Ltd. Activated leukocyte composition and uses for wound healing
BR112013005610A2 (pt) * 2010-09-09 2019-09-24 Macrocure Ltd sobrenadante condicionado de leucócito, alcs, método para o tratamento de uma ferida, método para a inibição do surgimento de infecção em uma ferida, método, sobrenadante e produto
US20150030635A1 (en) 2012-03-15 2015-01-29 Macrocure, Ltd. Activated Immunostimulatory Cell Composition and Uses Thereof
MX2014010893A (es) 2012-03-15 2015-06-23 Macrocure Ltd Composicion celular inmunoestimulante activada para terapia de infecciones.
EP2781224A1 (en) * 2013-03-18 2014-09-24 Khorionyx Implantable preparations comrpsing globin insoluble at physiological pH and serum for regeneration of tissues and treatment of wounds.
EP3258945B1 (en) 2015-02-16 2020-10-07 Nayacure Therapeutics Ltd. Modified blood clots
GB201618106D0 (en) 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120821A (ja) * 1983-12-05 1985-06-28 Asahi Chem Ind Co Ltd 悪性腫瘍治療用白血球刺激材および刺激方法
US4751001A (en) * 1984-09-24 1988-06-14 Becton Dickinson And Company Blood partitioning apparatus
JPH02167071A (ja) * 1988-12-19 1990-06-27 Terumo Corp 非ヒト動物由来白血球系細胞の分離材、分離器および分離方法
JPH07102151B2 (ja) * 1994-06-03 1995-11-08 中外製薬株式会社 新規なポリペプチドの製造法
IL110195A (en) * 1994-07-03 2003-10-31 David Danon Method and system for cultivating macrophages
US6146890A (en) 1994-07-03 2000-11-14 Danon; David Method and system for cultivating macrophages
US5837233A (en) * 1995-03-17 1998-11-17 University Of California Method for treating tumors
JPH10259134A (ja) * 1997-01-16 1998-09-29 Sekisui Chem Co Ltd 創傷治癒促進剤
RU2143685C1 (ru) * 1998-05-19 1999-12-27 Коган Александр Харитонович Способ дифференциального подсчета гранулоцитов, моноцитов и лимфоцитов
CN1335757A (zh) * 1998-11-12 2002-02-13 聚合体生物科学公司 可用于快速凝血和止血的止血聚合物
KR20100087781A (ko) * 2001-11-21 2010-08-05 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 인간 단핵 식세포성 백혈구의 제조 방법
JP4108393B2 (ja) * 2002-07-15 2008-06-25 テルモ株式会社 細胞増殖剤の製造方法
JP4245324B2 (ja) * 2002-10-09 2009-03-25 旭化成クラレメディカル株式会社 単球の分離回収方法
EP2201954A1 (en) * 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture

Also Published As

Publication number Publication date
WO2010100570A2 (en) 2010-09-10
BRPI1006759A2 (pt) 2016-03-15
RU2011139016A (ru) 2013-04-10
ZA201107269B (en) 2014-03-26
IL214953A0 (en) 2011-11-30
ES2428102T3 (es) 2013-11-05
EP2403509B1 (en) 2013-08-21
RU2015102067A (ru) 2015-06-20
CA2754190A1 (en) 2010-09-10
WO2010100570A3 (en) 2010-12-16
CN102438635B (zh) 2014-09-17
JP2012519681A (ja) 2012-08-30
JP5713924B2 (ja) 2015-05-07
AU2010220132B2 (en) 2013-10-10
EP2650001B1 (en) 2016-09-07
EP2403509A2 (en) 2012-01-11
KR20120002530A (ko) 2012-01-05
PL2403509T3 (pl) 2013-11-29
KR101548783B1 (ko) 2015-08-31
AU2010220132A1 (en) 2011-10-13
JP2015129180A (ja) 2015-07-16
RU2548741C2 (ru) 2015-04-20
CA2867976A1 (en) 2010-09-10
DK2403509T3 (da) 2013-09-16
EP2650001A1 (en) 2013-10-16
CN102438635A (zh) 2012-05-02

Similar Documents

Publication Publication Date Title
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CU20140141A7 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas
IN2012DN00971A (enExample)
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
PH12012501838A1 (en) Aptamers to ãŸ-ngf and their use in treating ãŸ-ngf mediated diseases and disorders
EA201001639A1 (ru) Композиции и способы их получения и применения
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
MX2012000434A (es) Metodo de sanacion de herida y modulacion de cicatriz.
IN2014DN06104A (enExample)
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
MX2011009277A (es) Composicion de leucocito activada.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
IL207310A0 (en) Vaccine compositions
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
WO2011100330A3 (en) Compositions and methods for preventing or treating a human parvovirus infection
MX2013002539A (es) Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas.
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN

Legal Events

Date Code Title Description
FG Grant or registration